(Q34374372)

1 August 2017

NAFLD, NASH and liver cancer (English)

1 reference

1 August 2017

Gregory A Michelotti

1

1 reference

1 August 2017

Mariana V Machado

series ordinal

2

1 reference

1 August 2017

Anna Mae Diehl

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

1 August 2017

10

1 reference

Nature Reviews Gastroenterology & Hepatology

inferred from page(s)

published in

1 reference

1 August 2017

10

1 reference

1 August 2017

11

1 reference

1 August 2017

656-665

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2013.183

1 August 2017

0 references

cites work

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatitis C in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Mechanisms of cardiodepression by an Na+-H+ exchange inhibitor methyl-N-isobutyl amiloride (MIA) on the heart: lack of beneficial effects in ischemia-reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Body-mass index and progression of hepatitis B: a population-based cohort study in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Epidemiology of hepatocellular carcinoma: consider the population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Metabolic roles of AMPK and metformin in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Molecular basis of NF-κB signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-κB, inflammation, and metabolic disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-kappaB as a critical link between inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Signals from dying hepatocytes trigger growth of liver progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

NF-κB essential modifier is required for hepatocyte proliferation and the oval cell reaction after partial hepatectomy in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The transcription factor Pokemon: a new key player in cancer pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Homeostatic regulatory role of Pokemon in NF-κB signaling: stimulating both p65 and IκBα expression in human hepatocellular carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Akt2 is required for hepatic lipid accumulation in models of insulin resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The critical role of AKT2 in hepatic steatosis induced by PTEN loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

PTEN-deficient intestinal stem cells initiate intestinal polyposis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

PTEN, stem cells, and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Pten dose dictates cancer progression in the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Tenets of PTEN tumor suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

S-Adenosylmethionine in cell growth, apoptosis and liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Deletion of murine choline dehydrogenase results in diminished sperm motility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

S-adenosylmethionine in liver health, injury, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Prohibitin-1 deficiency promotes inflammation and increases sensitivity to liver injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Dual role of microRNAs in NAFLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNAs in metabolism and metabolic disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

miR-29b regulates migration of human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Functional analysis of microRNAs in human hepatocellular cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IκB kinase alpha and TAB3 in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Steatotic liver: a suitable source for the isolation of hepatic progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Identification of metastasis-related microRNAs in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Role of receptors in human and rodent hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espírito Santo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.183

Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma

31 March 2020

1 reference

12 December 2020

Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma

1 reference

12 December 2020

The prevalence and etiology of elevated aminotransferase levels in the United States

1 reference

12 December 2020

Smoothened is a master regulator of adult liver repair

1 reference

12 December 2020

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

12 December 2020

Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients.

1 reference

12 December 2020

Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?

1 reference

12 December 2020

10.1038/NRGASTRO.2013.183

Identifiers

DOI

1 reference

1 August 2017

1 reference